CN101802198B - 免疫原性多肽和单克隆抗体 - Google Patents

免疫原性多肽和单克隆抗体 Download PDF

Info

Publication number
CN101802198B
CN101802198B CN200880108203.5A CN200880108203A CN101802198B CN 101802198 B CN101802198 B CN 101802198B CN 200880108203 A CN200880108203 A CN 200880108203A CN 101802198 B CN101802198 B CN 101802198B
Authority
CN
China
Prior art keywords
polypeptide
seq
phtd
composition
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880108203.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN101802198A (zh
Inventor
M·奥赫斯
R·布鲁克斯
R·夏尔博瓦
J·耶雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Publication of CN101802198A publication Critical patent/CN101802198A/zh
Application granted granted Critical
Publication of CN101802198B publication Critical patent/CN101802198B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
CN200880108203.5A 2007-07-23 2008-07-23 免疫原性多肽和单克隆抗体 Expired - Fee Related CN101802198B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96172307P 2007-07-23 2007-07-23
US60/961723 2007-07-23
PCT/CA2008/001353 WO2009012588A1 (en) 2007-07-23 2008-07-23 Immunogenic polypeptides and monoclonal antibodies

Publications (2)

Publication Number Publication Date
CN101802198A CN101802198A (zh) 2010-08-11
CN101802198B true CN101802198B (zh) 2016-02-17

Family

ID=40280955

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880108203.5A Expired - Fee Related CN101802198B (zh) 2007-07-23 2008-07-23 免疫原性多肽和单克隆抗体

Country Status (12)

Country Link
US (1) US8337846B2 (https=)
EP (1) EP2183366B1 (https=)
JP (3) JP2010535015A (https=)
KR (1) KR101595234B1 (https=)
CN (1) CN101802198B (https=)
AU (1) AU2008280799B2 (https=)
BR (1) BRPI0814127A2 (https=)
CA (1) CA2694466A1 (https=)
ES (1) ES2397488T3 (https=)
IL (1) IL203429A0 (https=)
WO (1) WO2009012588A1 (https=)
ZA (1) ZA201001260B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
CN102802664B (zh) 2009-12-22 2017-04-05 赛诺菲巴斯德有限公司 免疫原性组合物
US9649372B2 (en) 2009-12-22 2017-05-16 Sanofi Pasteur Limited Immunogenic compositions and related methods
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
KR20140009281A (ko) 2010-12-03 2014-01-22 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 스트렙토코커스 뉴모니애에 대한 면역화를 위한 조성물
WO2012156391A1 (en) 2011-05-17 2012-11-22 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
US9279815B2 (en) 2012-02-01 2016-03-08 Oklahoma Medical Research Foundation Human Streptococcus pneumoniae antibodies and uses therefor
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CN105754952B (zh) * 2016-02-16 2020-07-10 中国农业科学院兰州兽医研究所 抗羊痘病毒k3l蛋白c末端的单克隆抗体及其应用
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
ES3063128T3 (en) * 2018-03-20 2026-04-15 Sanofi Pasteur Ltd Methods for determining adjuvanted protein concentration and percent adsorption using intrinsic fluorescence and system implemented to perform the method
EP4291306A1 (en) * 2021-02-09 2023-12-20 University of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1449446A (zh) * 2000-06-20 2003-10-15 夏尔生化公司 链球菌抗原
CN1477970A (zh) * 2000-09-15 2004-02-25 ʷ��˹���������������﹫˾ 疫苗
CN1680434A (zh) * 1999-03-26 2005-10-12 科特克斯(Om)有限公司 肺炎链球菌抗原

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL81370A (en) * 1986-02-07 1991-06-30 Genetic Systems Corp Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions
DE69233012T2 (de) * 1991-11-22 2003-11-06 Fattom, Ali Ibrahim Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i
US6582708B1 (en) * 2000-06-28 2003-06-24 The Procter & Gamble Company Tooth whitening substance
ES2322306T3 (es) 1998-12-21 2009-06-18 Medimmune, Inc. Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas.
ES2400280T3 (es) * 1998-12-23 2013-04-08 Id Biomedical Corporation Of Quebec Antígenos de estreptococos
US7128918B1 (en) * 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
AU2001269833A1 (en) * 2000-06-14 2001-12-24 Cytovax Biotechnologies, Inc. Use of coiled-coil structural scaffold to generate structure-specific peptides
US7074415B2 (en) * 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
GB0130215D0 (en) 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
EP1456231A2 (en) * 2001-12-20 2004-09-15 Shire Biochem Inc. Streptococcus antigens
US6720918B2 (en) * 2002-09-17 2004-04-13 Space Systems/Loral, Inc. Antenna distortion estimation and compensation
EP2333114A1 (en) * 2003-04-15 2011-06-15 Intercell AG S. pneumoniae antigens
KR20060034698A (ko) * 2003-07-10 2006-04-24 와이어쓰 홀딩스 코포레이션 화농성 연쇄상구균 시스테인 프로테아제의 재조합 발현 및이의 면역원성 조성물
US8105612B2 (en) * 2005-05-13 2012-01-31 Novartis Vaccines And Diagnostics, Inc. Serum resistance factors of gram positive bacteria
JP5509176B2 (ja) * 2011-10-21 2014-06-04 株式会社日立製作所 計算機システムおよび計算機システムにおけるモジュール引き継ぎ方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1680434A (zh) * 1999-03-26 2005-10-12 科特克斯(Om)有限公司 肺炎链球菌抗原
CN1449446A (zh) * 2000-06-20 2003-10-15 夏尔生化公司 链球菌抗原
CN1477970A (zh) * 2000-09-15 2004-02-25 ʷ��˹���������������﹫˾ 疫苗

Also Published As

Publication number Publication date
US8337846B2 (en) 2012-12-25
AU2008280799B2 (en) 2013-07-11
JP2010535015A (ja) 2010-11-18
KR101595234B1 (ko) 2016-02-26
JP2013212108A (ja) 2013-10-17
IL203429A0 (en) 2011-07-31
ES2397488T3 (es) 2013-03-07
WO2009012588A1 (en) 2009-01-29
JP6204053B2 (ja) 2017-09-27
EP2183366B1 (en) 2012-10-24
CA2694466A1 (en) 2009-01-29
KR20100053564A (ko) 2010-05-20
JP2016005482A (ja) 2016-01-14
BRPI0814127A2 (pt) 2015-02-03
EP2183366A4 (en) 2010-09-01
US20100297133A1 (en) 2010-11-25
EP2183366A1 (en) 2010-05-12
AU2008280799A1 (en) 2009-01-29
ZA201001260B (en) 2010-10-27
CN101802198A (zh) 2010-08-11

Similar Documents

Publication Publication Date Title
CN101802198B (zh) 免疫原性多肽和单克隆抗体
AU2009329782B2 (en) Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides
CA2660743C (en) Immunogenic pcpa polypeptides and uses thereof
PL197449B1 (pl) Wyizolowane polipeptydy, immunogenne fragmenty tych polipeptydów, wyizolowane polinukleotydy, wektor ekspresyjny, komórka gospodarza zawierająca taki wektor, sposób wytwarzania polipeptydu, sposób ekspresji polinukleotydu, kompozycja szczepionki, przeciwciało immunospecyficzne w stosunku do polipeptydu lub jego immunogennego fragmentu, sposób diagnozowania zakażenia Neisseria meningitidis, zastosowania kompozycji zawierającej polipeptyd lub jego immunogenny fragment, lub polinukleotyd i kompozycja terapeutyczna do leczenia choroby wywołanej przez Neisseria meningitidis
US20040131634A1 (en) Neisseria lactoferrin binding protein
AU2013204613A1 (en) Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides
WO2019023812A1 (en) VACCINE COMPOSITION AGAINST MALARIA AND METHOD THEREOF
US20130184200A1 (en) Immunogenic Polypeptides and Monoclonal Antibodies
Class et al. Patent application title: Immunogenic Polypeptides and Monoclonal Antibodies Inventors: Martina Ochs (Toronto, CA) Roger Brooks (Toronto, CA) Robert Charlebois (Toronto, CA) Jeremy Yethon (Milton, CA)
JP2011525112A (ja) β溶血性連鎖球菌株由来のＯＲＦ５５４の組成物および使用方法
AU2016254447A1 (en) Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides
HK1243089A1 (en) Immunogenic pcpa polypeptides and uses thereof
CN101115502A (zh) 抗脑膜炎奈瑟氏球菌的疫苗
CZ20004395A3 (cs) Antigenní polypeptidy Neisseria meningitidis, příslušné polynukleotidy a protektivní protilátky
EP1976556A2 (en) Neisseria meningitidis vaccines and their use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160217

Termination date: 20180723

CF01 Termination of patent right due to non-payment of annual fee